
|Videos|February 1, 2023
Use of Sotorasib in Patients with KRASG12C mutated NSCLC
Author(s)Mark Socinski, MD, Joshua K. Sabari, MD
Drs Socinski and Sabari comment on the use of sotorasib in patients with KRASG12C-mutated NSCLC with brain metastases and review data from the CodeBreak 100 and CodeBreak 200 trials.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Daratumumab Quadruplet for Transplant-Ineligible Myeloma
2
Atebimetinib Combo Shows Compelling 1-Year OS in First-Line Pancreatic Cancer
3
FDA Grants Fast Track Designation to IBI3003 for R/R Multiple Myeloma
4
Tafasitamab Combo Significantly Extends PFS in R/R Follicular Lymphoma
5



















